Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04250259
PHASE2

SAMe Trial for Patients With Alcoholic Cirrhosis

Sponsor: Indiana University

View on ClinicalTrials.gov

Summary

The proposed of this randomized, double blinded, placebo-controlled study is to assess the effect of SAMe compared to placebo in patients with alcoholic cirrhosis Child Class A and B. The primary objective of the study is to test relationship between SAMe (S-adenosylmethionine) supplement on liver function. The hypothesis is that SAMe supplement will improve liver function in patients with alcoholic liver disease. The improvement in liver function will lead to the reduction in all-cause mortality in patients with alcoholic cirrhosis in those who receive SAMe supplement when compared to those receiving placebo.

Official title: A Multi-center, Randomized, Placebo-controlled Trial of S-Adenosylmethionine (SAMe) in Patients With Alcoholic Cirrhosis

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

196

Start Date

2020-10-22

Completion Date

2027-03-01

Last Updated

2026-03-31

Healthy Volunteers

Yes

Interventions

DRUG

Placebo

2 tablets of placebo in the morning before breakfast and one tablet of placebo in the evening before dinner for 24 months

DRUG

SAMe 400 mg tablet

SAMe supplement (SAMe 400 mg tablet), 2 tablets in the morning before breakfast and one tablet in the evening before dinner (a total dose of 1,200 mg daily) for 24 months

Locations (2)

Cedars-Sinai Medical Center

Los Angeles, California, United States

Indiana University Hospital

Indianapolis, Indiana, United States